|
 MILAN (Reuters) - Italian vaccine vial maker Stevanato on Tuesday
slightly improved its guidance on full-year results after reporting
a 37% increase in third quarter revenue.
The family-controlled group, which listed on the New York Stock
Exchange in July, said it now expects full-year sales to be between
825-835 million euros ($953-$965 million), up from the 820-830
million euro range it forecast in August.
The company also raised the lower end of its expectations for both
core profits and adjusted diluted earnings per share(EPS),
indicating it now sees adjusted EBITDA to reach at least 214 million
euros and adjusted diluted EPS to be at least 0.45 euros, up from
212 million euros and 0.43 euros respectively.
[to top of second column] |
In the third quarter, revenue reached 214.5
million euros, with around 16% of the total
attributable to business linked to COVID-19.
Stevanato added it awarded a discretionary bonus
of 6.7 million euros to all its staff to
recognise their efforts over the past 18 months.
($1 = 0.8655 euros)
(Reporting by Francesca Landini, editing by
Giulia Segreti)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
